Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

详细信息    查看全文

• 作者：Ophelia Q. P. Yin (1) ophelia.yin@novartis.com
  Frank J. Giles (2)
  Michele Baccarani (3)
  Philipp le Coutre (4)
  Ovidiu Chiparus (1)
  Neil Gallagher (1)
  Giuseppe Saglio (5)
  Timothy P. Hughes (6)
  Andreas Hochhaus (7)
  Hagop M. Kantarjian (8)
  Richard A. Larson (9)
• 关键词：Nilotinib – ; Drug– ; drug interactions – ; Proton pump inhibitors – ; H2 blockers – ; Chronic myeloid leukemia
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：70
• 期：2
• 页码：345-350
• 全文大小：213.4 KB
• 参考文献：1. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141–1145
  2. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh Y, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841–851
  3. Yin OQP, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H (2010) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50:960–967
  4. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O’Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540–3546
  5. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, The ENESTnd Investigators (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259
  6. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA (1999) Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 65:369–376
  7. Rendic S, Ruf HH, Weber P, Kajfez F (1984) Cimetidine and ranitidine: their interaction with human and pig liver microsomes and with purified cytochrome P-450. Eur J Drug Metab Pharmacokinet 9:195–200
  8. Yin OQ, Gallagher N, Li A, Zhou W, Harrell R, Schran H (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50:188–194
  9. Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, Blackwood-Chirchir A, Bertz R (2009) Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 49:700–709
  10. Takahashi N, Miura M, Niioka T, Sawada K (2011) Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2011 Dec 7 [Epub ahead of print]
  11. OSI Pharmaceuticals, LLC (2010) Tarceva庐 (erlotinib) Prescribing information. Farmingdale, NY, USA
  12. Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, Bednarczyk E, Morse GD (2006) Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 26:341–346
  13. Burger DM, Hugen PW, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA (1998) Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 12:2080–2082
  14. Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, Redner RL, Miller BM, Beumer JH (2009) Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 68:370–374
  15. Miner P Jr, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616–2620
  16. Rohss K, Lind T, Wilder-Smith C (2004) Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60:531–539
  17. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551–557
  18. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67:44–49
  19. Hiwase DK, Eadie L, Saunders V, Hughes T, White DL (2010) Proton pump inhibitors augment nilotinib and dasatinib mediated Bcr-Abl kinase inhibition. Blood 116:1626 (abstr 3991)
• 作者单位：1. Oncology Clinical Pharmacology, Novartis Pharmaceuticals Corporation, 180 Park Ave [104-3K20], Florham Park, NJ 07932, USA2. HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland3. University of Bologna, Bologna, Italy4. Charit茅, Campus Virchow-Klinikum, Universit盲tsmedizin Berlin, Berlin, Germany5. University of Turin, Orbassano, Italy6. SA Pathology, Royal Adelaide Hospital, Adelaide, Australia7. Universit盲tsklinikum Jena, Jena, Germany8. The University of Texas MD Anderson Cancer Center, Houston, TX, USA9. University of Chicago, Chicago, IL, USA
• ISSN：1432-0843

文摘

Purpose The impact of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2 blockers) on the efficacy of nilotinib was evaluated.